Explore

Rapid Read Rapid Read
ASCO Conference Highlights Breakthroughs in Cancer Treatment

ASCO Conference Highlights Breakthroughs in Cancer Treatment

The American Society of Clinical Oncology (ASCO) conference in Chicago showcased significant advancements in cancer treatment, with researchers presenting data that could reshape the cancer landscape. Eli Lilly's RET inhibitor Retevmo demonstrated a substantial reduction in disease risk for early-stage lung cancer patients. Other notable developments included BioNTech and Bristol Myers Squibb's bispecific antibodies showing promising results in lung cancer trials. Johnson & Johnson's Erleada improved outcomes for high-risk prostate cancer patients, and Incyte's Monjuvi showed potential in treating diffuse large B cell lymphoma. These findings represent a shift in cancer treatment paradigms, offering new hope for patients.
Trendline Trendline
AstraZeneca Seeks FDA Approval for Camizestrant in Breast Cancer Treatment Despite Advisory Committee Setback

AstraZeneca Seeks FDA Approval for Camizestrant in Breast Cancer Treatment Despite Advisory Committee Setback

AstraZeneca Seeks FDA Approval for Camizestrant in Breast Cancer Treatment Despite Advisory Committee Setback
Trendline Trendline
Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%

Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%

Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%
Rapid Read Rapid Read
Clinical Trials Show Promising Results for Cancer Treatment Injection

Clinical Trials Show Promising Results for Cancer Treatment Injection

Recent clinical trials have demonstrated promising results for a cancer treatment injection known as amivantamab, developed by Johnson & Johnson. The drug was tested in an 11-nation trial involving patients whose cancer had either spread or returned after other treatments failed. The trial included 102 patients with head and neck cancer, where tumors shrank or disappeared in 43 patients. Notably, 28 patients experienced tumor shrinkage, while 15 saw their tumors completely disappear. The injection has also shown similar results in patients with certain types of lung cancer, with tumors shrinking in more than a third of patients. The drug works by targeting a protein that aids tumor growth and blocking pathways used by cancer cells to resist treatment, while also activating the immune system to assist in treatment. The results of the trial are set to be presented at the American Society of Clinical Oncology annual meeting in Chicago.
Rapid Read Rapid Read
Citius Oncology Presents Phase 1 Data on LYMPHIR in Combination with Pembrolizumab for Gynecologic Malignancies

Citius Oncology Presents Phase 1 Data on LYMPHIR in Combination with Pembrolizumab for Gynecologic Malignancies

Citius Oncology has presented Phase 1 clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting, evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab for recurrent or refractory gynecologic malignancies. The study demonstrated durable responses and manageable tolerability in heavily pre-treated patients, with a 20.5-month median progression-free survival observed among 48% of efficacy-evaluable patients. The combination therapy showed a 33% objective response rate in patients with relapsed or refractory endometrial cancer. LYMPHIR's ability to deplete immunosuppressive regulatory T-cells may enhance the effect of checkpoint inhibitors, offering a potential therapeutic option for patients with limited treatment options.
Rapid Read Rapid Read
MEDSIR's New Therapeutic Strategy Shows Promise in Advanced Prostate Cancer Treatment

MEDSIR's New Therapeutic Strategy Shows Promise in Advanced Prostate Cancer Treatment

MEDSIR, an international oncology research company, has presented the final results of its ZZ-FIRST study at the ASCO scientific congress in Chicago. The study explores a new therapeutic strategy for patients with high-volume metastatic hormone-sensitive prostate cancer. This approach combines enzalutamide, a next-generation hormonal treatment, with talazoparib, a PARP inhibitor, to intensify standard therapy. The goal is to block tumor progression before the cancer develops resistance to treatment. The study enrolled 54 patients from Spanish centers and demonstrated that the combination therapy resulted in a radiographic progression-free survival of 45.3 months, compared to 31.1 months with enzalutamide alone. This suggests a significant improvement in delaying tumor progression.
Rapid Read Rapid Read
Immuneering's Drug Extends Survival in Pancreatic Cancer Patients by Nine Months

Immuneering's Drug Extends Survival in Pancreatic Cancer Patients by Nine Months

Immuneering's investigational drug, atebimetinib, has shown promising results in a Phase 2a trial for pancreatic cancer, extending median overall survival by nearly nine months compared to standard treatments. The drug, combined with modified gemcitabine/nab-paclitaxel, demonstrated a median overall survival of 17.3 months. The trial results were presented at the American Society of Clinical Oncology (ASCO) meeting, highlighting the drug's potential as a first-line treatment for metastatic pancreatic cancer.
Rapid Read Rapid Read
Johnson Johnson's Erleada Shows Promising Results in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promising Results in Prostate Cancer Treatment

A recent study presented at the ASCO conference revealed that Johnson & Johnson's drug Erleada (apalutamide) significantly improves outcomes for patients undergoing radical prostatectomy for high-risk localized prostate cancer. The study involved 2,109 participants and demonstrated that adding Erleada to the standard treatment regimen increased the likelihood of a complete or nearly complete response from 1% to 8.9%. Additionally, patients experienced a 29% lower risk of recurrence and a 20% lower risk of metastasis, with a median survival of 57.1 months compared to 38.4 months in the control group. The trial, which is the largest of its kind, suggests that Erleada could set a new standard for treating this type of cancer.
USA Today USA Today
Weight-loss drugs linked to lower breast cancer rates. What to know

Weight-loss drugs linked to lower breast cancer rates. What to know

A study of more than 110,000 women found those who took popular GLP-1 drugs prescribed for obesity or diabetes had a lower risk of breast cancer.
AP News AP News
Experimental pill promises new hope for deadly pancreatic cancer

Experimental pill promises new hope for deadly pancreatic cancer

New research shows a novel pill is helping people with advanced pancreatic cancer live longer
Trendline Trendline
Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial, Potentially Expanding Treatment Options

Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial, Potentially Expanding Treatment Options

Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial, Potentially Expanding Treatment Options
Reuters Reuters
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage